Does the media refer more to MCRB or ORGO?

In the previous week, Organogenesis had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Organogenesis' score of 0.54 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MCRB or DTIL?

In the previous week, Precision BioSciences had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Precision BioSciences' score of 0.20 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NBP or MCRB more profitable?

I-Mab has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Seres Therapeutics -1,192.94% -114.82% -34.15%

Does the media refer more to NGEN or MCRB?

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Seres Therapeutics' score of 0.94 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MCRB or MDWD?

In the previous week, MediWound had 4 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for MediWound and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat MediWound's score of 0.33 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Seres Therapeutics (MCRB) Competitors

$3.79 -0.23 (-5.72%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.11 (+2.90%)

As of 04:30 AM Eastern

Compare

MCRB vs. ORGO, DTIL, NBP, NGEN, and MDWD

Should you buy Seres Therapeutics stock or one of its competitors? Seres Therapeutics's main competitors and comparable companies include Organogenesis (ORGO), Precision BioSciences (DTIL), I-Mab (NBP), NervGen Pharma (NGEN), and MediWound (MDWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Seres Therapeutics compare to Organogenesis?

Seres Therapeutics (NASDAQ:MCRB) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Seres Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 348.55%. Organogenesis has a consensus price target of $4.33, suggesting a potential upside of 198.85%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Organogenesis had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Organogenesis' score of 0.54 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Seres Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A
Organogenesis	$564.17M	0.33	$37.03M	-$0.86	N/A

Organogenesis has a net margin of -19.94% compared to Seres Therapeutics' net margin of -1,192.94%. Organogenesis' return on equity of -23.89% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Organogenesis	-19.94%	-23.89%	-11.13%

Summary

Organogenesis beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Precision BioSciences?

Seres Therapeutics (NASDAQ:MCRB) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 2.7% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 348.55%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 407.08%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Seres Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Seres Therapeutics has higher earnings, but lower revenue than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A

In the previous week, Precision BioSciences had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Precision BioSciences' score of 0.20 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision BioSciences has a net margin of -96.73% compared to Seres Therapeutics' net margin of -1,192.94%. Precision BioSciences' return on equity of -72.52% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Precision BioSciences	-96.73%	-72.52%	-32.25%

Summary

Precision BioSciences beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to I-Mab?

I-Mab (NASDAQ:NBP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Seres Therapeutics has lower revenue, but higher earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	45.49	-$46.27M	-$0.36	N/A
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A

In the previous week, I-Mab and I-Mab both had 1 articles in the media. Seres Therapeutics' average media sentiment score of 0.94 beat I-Mab's score of -1.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Negative
Seres Therapeutics	Positive

I-Mab has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

I-Mab currently has a consensus price target of $9.00, indicating a potential upside of 488.24%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 348.55%. Given I-Mab's higher probable upside, equities analysts clearly believe I-Mab is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

I-Mab has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Summary

I-Mab beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Seres Therapeutics' score of 0.94 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NervGen Pharma currently has a consensus target price of $14.00, suggesting a potential upside of 614.29%. Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 348.55%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe NervGen Pharma is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

59.3% of Seres Therapeutics shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NervGen Pharma has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Seres Therapeutics has higher revenue and earnings than NervGen Pharma. NervGen Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A

Summary

NervGen Pharma beats Seres Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Seres Therapeutics compare to MediWound?

Seres Therapeutics (NASDAQ:MCRB) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Seres Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 348.55%. MediWound has a consensus target price of $33.00, indicating a potential upside of 141.76%. Given Seres Therapeutics' higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Seres Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

In the previous week, MediWound had 4 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for MediWound and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat MediWound's score of 0.33 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A

MediWound has a net margin of -170.10% compared to Seres Therapeutics' net margin of -1,192.94%. MediWound's return on equity of -47.24% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
MediWound	-170.10%	-47.24%	-24.27%

Summary

MediWound beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.38M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.56	13.88	274.09	25.69
Price / Sales	48.21	1,353.16	642.55	79.71
Price / Cash	3.70	113.29	77.80	52.76
Price / Book	0.78	15.40	10.47	6.32
Net Income	$5.70M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.56%	-1.74%	-0.68%	0.17%
1 Month Performance	-18.67%	-6.20%	-3.18%	-3.27%
1 Year Performance	-80.45%	30.64%	15.12%	5.58%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	3.0551 of 5 stars	$3.79 -5.7%	$17.00 +348.5%	-78.4%	$40.38M	$790K	N/A	66
ORGO Organogenesis	1.7612 of 5 stars	$1.47 -2.3%	$4.33 +195.8%	-69.5%	$188.52M	$564.17M	N/A	950	Positive News
DTIL Precision BioSciences	2.1819 of 5 stars	$6.76 -1.5%	$32.25 +377.4%	+30.3%	$186.34M	$45.06M	N/A	67	News Coverage
NBP I-Mab	2.2951 of 5 stars	$1.59 -1.6%	$9.00 +467.8%	N/A	$183.30M	N/A	N/A	380	Negative News
NGEN NervGen Pharma	2.0265 of 5 stars	$2.15 -1.8%	$14.00 +551.2%	N/A	$174.57M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. ORGO, DTIL, NBP, NGEN, and MDWD

How does Seres Therapeutics compare to Organogenesis?

Summary

How does Seres Therapeutics compare to Precision BioSciences?

Summary

How does Seres Therapeutics compare to I-Mab?

Summary

How does Seres Therapeutics compare to NervGen Pharma?

Summary

How does Seres Therapeutics compare to MediWound?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. ORGO, DTIL, NBP, NGEN, and MDWD

How does Seres Therapeutics compare to Organogenesis?

Do analysts recommend MCRB or ORGO?

Do insiders & institutionals have more ownership in MCRB or ORGO?

Does the media refer more to MCRB or ORGO?

Which has more risk & volatility, MCRB or ORGO?

Which has higher earnings & valuation, MCRB or ORGO?

Is MCRB or ORGO more profitable?

Summary

How does Seres Therapeutics compare to Precision BioSciences?

Do insiders and institutionals have more ownership in MCRB or DTIL?

Do analysts rate MCRB or DTIL?

Which has more volatility and risk, MCRB or DTIL?

Which has stronger earnings & valuation, MCRB or DTIL?

Does the media refer more to MCRB or DTIL?

Is MCRB or DTIL more profitable?

Summary

How does Seres Therapeutics compare to I-Mab?

Which has better earnings & valuation, NBP or MCRB?

Does the media prefer NBP or MCRB?

Is NBP or MCRB more profitable?

Do analysts recommend NBP or MCRB?

Do insiders & institutionals believe in NBP or MCRB?

Which has more volatility & risk, NBP or MCRB?

Summary

How does Seres Therapeutics compare to NervGen Pharma?

Does the media refer more to NGEN or MCRB?

Do analysts recommend NGEN or MCRB?

Do institutionals & insiders have more ownership in NGEN or MCRB?

Is NGEN or MCRB more profitable?

Which has preferable earnings & valuation, NGEN or MCRB?

Summary

How does Seres Therapeutics compare to MediWound?

Do institutionals and insiders believe in MCRB or MDWD?

Do analysts rate MCRB or MDWD?

Which has more volatility and risk, MCRB or MDWD?

Does the media favor MCRB or MDWD?

Which has higher earnings and valuation, MCRB or MDWD?

Is MCRB or MDWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools